Invion Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVIXF research report →
Price Chart
About the company
Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts.
- CEO
- Thian Chew
- IPO
- 2013
- Employees
- 4
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on IVIXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.03M
- P/E
- -0.30
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 0.58
- EV/EBITDA
- -0.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -150.48%
- ROIC
- -106.56%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-849,206-123.0%
- Op Income
- $-3,479,287
- Net Income
- $-5,796,848-3.0%
- EPS
- $-0.08-37.8%
- OCF Growth
- -22.1%
- FCF Growth
- +21.9%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- 0.40
- RSI (14)
- 1
- Avg Volume
- 0
No earnings-call transcripts are available for IVIXF yet.
- Free Float
- 60.1%
- Shares Outstanding
- 109.20M
- Float Shares
- 65.63M
Our IVIXF coverage
Recent articles, reports, and earnings notes.
No research on IVIXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVIXF report →